Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 20 de 6929 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Tatsioni A, Karassa FB, Goodman SN, Zarin DA, Fanelli D, Ioannidis JPA. Lost evidence from registered large long-unpublished randomized controlled trials: a survey. Ann Intern Med 2019:7 de mayo. [Ref.ID 103117]
3.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
4.Enlace a cita original Cita con resumen
Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]
6.Enlace a cita original Cita con resumen
Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. FDA U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]
9.Enlace a cita original Cita con resumen
Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLOS Medicine 2019:13 de marzo. [Ref.ID 103076]
10.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019:25 de marzo. [Ref.ID 103073]
11.Enlace a cita original Cita con resumen
Anónimo. FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. FDA U.S. Food and Drug Administration 2019:22 de marzo. [Ref.ID 103071]
12. Cita con resumen
Brownlee S, Garber J. Overprescribed: High cost isn’t America’s only drug problem. STAT Daily Recap 2019:2 de abril. [Ref.ID 103070]
13.Enlace a cita original Cita con resumen
Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, Devivo M, Chang T, Fox J, Brevik C, Williamson K, Abbott D. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med 2019:26 de marzo. [Ref.ID 103069]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cortese S. Psychosis during attention deficit–hyperactivity disorder treatment with stimulants. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103068]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]
17. Cita con resumen
McQuaid J. Asthma takes a hard toll on African-Americans. Can precision medicine ease the burden?. STAT Daily Recap 2019:26 de marzo. [Ref.ID 103064]
19. Cita con resumen
Silverman E. STAT Plus: AbbVie is sued for using Humira patent deals to block competition in the U.S.. STAT Daily Recap 2019:20 de marzo. [Ref.ID 103062]
20.Enlace a cita original Cita con resumen
Beall RF, Hwang TJ, Kesselheim AS. Major events in the life course of new drugs, 2000–2016. N Engl J Med 2019;380:14 de marzo. [Ref.ID 103056]
Seleccionar todas
 
 1 a 20 de 6929 siguiente >>